Alnylam Pharma (ALNY) Tops Q4 EPS by 64c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $239.56 -2.42%
EPS Growth %: -39.0%
Financial Fact:
Net loss: -90.13M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -39.0%
Financial Fact:
Net loss: -90.13M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of $0.06, $0.64 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $593.16 million versus the consensus estimate of $580.61 million.
GUIDANCE:
Alnylam Pharma sees FY2025 revenue of $2.05-2.25 billion, versus the consensus of $2.68 billion.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. and Denmark close in on a Greenland deal - Reuters
- Teva shares Phase 3 data on once-monthly schizophrenia injection
- SmartKem (SMTK) files for 15.13M share offering by selling stockholders
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
